Key result
VA-ECLS is linked to an ~80% myocardial recovery rate in severe acute myocarditis.
Why the study?
Acute myocardial failure from myocarditis is highly lethal and the role of venoarterial extracorporeal life support in left ventricular decompression and myocardial recovery remains uncertain.
Does venoarterial extracorporeal life support (ECLS) improve myocardial recovery and survival in patients with acute myocarditis and refractory myocardial failure?
Observational (n=5)
Does venoarterial extracorporeal life support (ECLS) improve myocardial recovery and survival in patients with acute myocarditis and refractory myocardial failure?
Venoarterial ECLS is a feasible and effective strategy to stabilize patients with acute myocarditis and refractory cardiogenic shock, serving as a bridge to myocardial recovery or transplantation.
VA-ECLS may aid recovery in fulminant myocarditis; leaves open whether it achieves LV decompression comparable to LVAD.
Acute myocardial failure associated with myocarditis is highly lethal. Left ventricular assist device support for these patients has been advocated to decompress the left ventricle and facilitate myocardial remodeling and recovery. Concerns exist regarding the ability of venoarterial (VA) extracorporeal life support (ECLS) to decompress the left ventricle and allow effective myocardial recovery. ECLS has several advantages, including availability, rapid deployment, and flexibility, as compared with contemporary ventricular assist devices. The objective of this study was to provide a brief review of acute myocarditis and present our series of patients. After Institutional Review Board approval, we conducted a retrospective data analysis of patients on ECLS experiencing rapidly progressive myocardial failure from a normal baseline. Patients with a history of intrinsic heart disease were excluded. All patients were thought to have myocarditis and had failed medical therapy requiring emergent ECLS support. Five patients demographics are detailed in Table 1. Patients experienced life-threatening intractable dysrhythmias or cardiac arrest and were refractory to medical therapy with severe acidosis and impending multisystem organ failure. All patients were stabilized with VA ECLS, and the left ventricle and atrium were decompressed in four of five patients. A left atrial vent was placed in one patient. Myocardial recovery with successful weaning from ECLS was obtained in four of five patients and to a normal ejection fraction in three of the five. One patient failed ECLS weaning and required biventricular VAD support secondary to severe myocardial necrosis from giant cell myocarditis and was transplanted, one died, all others are alive at follow-up. ECLS is safe and effective to treat acute myocardial failure and may be used to obtain myocardial recovery in certain subsets. We devised a decision algorithm for ECLS deployment in this patient cohort and routinely use ECLS.
No takes yet. Share an insight, caveat, or question.
Sowell et al. (2012) conducted an observational in Acute myocarditis with rapidly progressive myocardial failure (n=5). Venoarterial (VA) extracorporeal life support (ECLS) was evaluated on Myocardial recovery with successful weaning from ECLS. Venoarterial extracorporeal life support (ECLS) facilitated myocardial recovery and successful weaning in 80% (4 of 5) of patients with acute myocarditis and severe myocardial failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: